Tc-99m sestamibi thyroid imaging in patients on chronic amiodarone treatment: a comparison with Tc-99m pertechnetate imaging.

PURPOSE OF THE REPORT: To compare thyroid imaging using Tc-99m sestamibi with the standard Tc-99m pertechnetate scintigraphy in patients on chronic use of amiodarone. MATERIALS AND METHODS: A total of 23 patients on oral amiodarone for at least 4 months had thyroid scintigraphy and uptake measurement using Tc-99m pertechnetate and Tc-99m sestamibi. Thyroid function was evaluated by measuring serum concentrations of thyrotropin, free thyroxine, and free triiodothyronine, and antithyroglobulin and antithyroperoxidase antibodies. RESULTS: Ten of the 23 patients were euthyroid, 9 hypothyroid, and 4 hyperthyroid, with normal, increased, and decreased serum thyrotropin, respectively. All euthyroid patients had markedly decreased thyroid Tc-99m pertechnetate uptake and normal or slightly increased Tc-99m sestamibi uptake, except for one patient who had increased uptake of both radiotracers. One of the 4 hyperthyroid patients had Graves' disease and markedly increased thyroid uptake of both tracers. The other 3 hyperthyroid patients had normal or decreased Tc-99m pertechnetate uptake and increased Tc-99m sestamibi uptake. Differently than expected, all 9 hypothyroid patients had normal or increased uptake of both radiopharmaceuticals. CONCLUSIONS: This study suggests that Tc-99m sestamibi may be an alternative tracer for thyroid scintigraphy and uptake measurement of patients on chronic use of amiodarone. Tc-99m sestamibi seems to be better than Tc-99m pertechnetate for the scintigraphic evaluation of the thyroid of euthyroid and hyperthyroid patients.

Estimation of absolute renal uptake with technetium-99m dimercaptosuccinic acid: direct comparison with the radioactivity of nephrectomy specimens / Estimativa da captação renal absoluta com ácido dimercaptosuccínico marcado com tecnécio-99m: comparação direta com a radioatividade medida em peças de nefrectomi

CONTEXT AND OBJECTIVE: Studies using radionuclides are the most appropriate method for estimating renal function. Dimercaptosuccinic acid chelate labeled with technetium-99m (99mTc-DMSA) is the radiopharmaceutical of choice for high-resolution imaging of the renal cortex and estimation of the functional renal mass. The aim of this study was to evaluate a simplified method for determining the absolute renal uptake (ARU) of 99mTc-DMSA prior to nephrectomy, using the radioactivity counts of nephrectomy specimens as the gold standard. DESIGN AND SETTING: Prospective study at the Division of Nuclear Medicine, Department of Radiology, Universidade Estadual de Campinas. METHODS: Seventeen patients (12 females; range 22-82 years old; mean age 50.8 years old) underwent nephrectomy for various reasons. Renal scintigraphy was performed three to four hours after intravenous administration of a mean dose of 188.7 MBq (5.1 mCi) of 99mTc-DMSA, which was done six to 24 hours before surgery. The in vivo renal uptake of 99mTc-DMSA was determined using the radioactivity of the syringe before the injection (measured using a dose calibrator) and the images of the syringe and kidneys, obtained from a scintillation camera. After surgery, the reference value for renal uptake of 99mTc-DMSA was determined by measuring the radioactivity of the nephrectomy specimen using the same dose calibrator. RESULTS: The ARU measurements were very similar to those obtained using the reference method, as determined by linear regression (r-squared = 0.96). CONCLUSION: ARU estimation using the proposed method before nephrectomy seems to be accurate and feasible for routine use.

CONTEXTO E OBJETIVO: Os estudos com radionuclídeos são os mais adequados para se estimar a função renal. O ácido dimercaptosuccínico marcado com tecnécio-99m (DMSA-99mTc) é o radiofármaco de escolha para imagens de alta resolução dos rins, permitindo, também, estimar massa de parênquima renal funcionante. O objetivo deste estudo foi avaliar um método mais simples para determinar-se a captação renal absoluta (CRA) de DMSA-99mTc antes de nefrectomias e validá-lo utilizando-se as contagens radioativas das próprias peças de nefrectomia como padrão-ouro. TIPO DE ESTUDO E LOCAL: Estudo prospectivo, desenvolvido no Serviço de Medicina Nuclear do Departamento de Radiologia da Universidade Estadual de Campinas. MÉTODOS: Foram estudados 17 pacientes (12 pacientes do sexo feminino, média de idade de 50,8 anos), selecionados para a realização de nefrectomia. A cintilografia renal foi realizada três a quatro horas após a administração venosa de 188,7 MBq de DMSA-99mTc, seis a 24 horas antes da cirurgia. A CRA in vivo foi determinada utilizando-se a radioatividade da seringa antes da injeção (medida com um calibrador de dose) e as imagens da seringa e dos rins, obtidas em uma câmara de cintilação. Após a cirurgia, o valor de referência para a CRA foi determinado medindo-se a radioatividade da peça de nefrectomia com o mesmo calibrador de dose. RESULTADOS: Os valores de CRA foram muito semelhantes àqueles obtidos com o método de referência, conforme foi demonstrado pela análise de regressão linear (r-quadrado = 0,96). CONCLUSÃO: A estimativa da CRA com o método proposto antes de nefrectomiasparece ser acurado e aplicável ao uso rotineiro.